Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, intravenous corticosteroid pulse therapy for rapidly progressive alopecia areata showed that 74.5% of patients achieved a good response in the long-term, and a revised scoring system predicted relapse risk effectively in cases with preceding infectious symptoms.

High-dose corticosteroids can significantly regrow hair in severe alopecia areata.

In this study, the combination of pulse intravenous corticosteroids and methotrexate was associated with positive hair regrowth in severe alopecia areata patients, with half achieving total regrowth.

This study found that intravenous high-dose pulse corticosteroids resulted in a complete response in 38% of children with alopecia areata, but the majority of responders relapsed within a year.

In this retrospective study, researchers observed that additional rounds of intravenous corticosteroid pulse therapy led to only partial hair regrowth in some rapidly progressive alopecia areata cases, with all participants experiencing relapse, indicating limited efficacy for severe cases resistant to initial treatment.

This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.

This study found that intralesional Diprospan injections and high-dose intravenous methylprednisolone may be effective for treating longstanding multifocal alopecia areata, with variable hair regrowth observed among patients.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

This case study reports a rare coexistence of alopecia areata and lichen planopilaris in a 37-year-old woman and highlights the importance of targeting active scalp areas for biopsy to appropriately manage coexisting scarring and non-scarring alopecias, with distinct therapeutic priorities.

This study found that pulse corticosteroids effectively induce hair regrowth in alopecia areata, with betamethasone showing higher efficacy but more side effects, and treatment success varying depending on age, onset time, and disease type.

This study found that methylprednisolone pulse therapy may be an effective treatment option for patients with severe multifocal alopecia areata, particularly those experiencing their first episode.

This study reviewed 20 studies and found that pulse corticosteroid therapy led to complete hair regrowth in 38.53% of patients with severe alopecia areata, but came with many unwanted side effects.

Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.

This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.

In this case study, an 11-year-old boy with extensive alopecia areata showed 80% hair regrowth after six months of treatment with methylprednisolone despite initial lack of response to topical therapies.

This study observed that while dexamethasone-cyclophosphamide pulse therapy is relatively free from hypertension and diabetes compared to conventional steroids in pemphigus patients, it frequently causes generalized weakness and flushing.

In this case study, intravenous cyclophosphamide pulse therapy effectively improved symptoms of steroid-resistant lupus cystitis and peritonitis, allowing for a reduction in steroid dosage.

In this study, oral steroid pulse therapy was found to be as effective and well-tolerated as intravenous pulse therapy in treating severe alopecia areata, especially when started within one year of disease onset.

The researchers reported a case of a young girl with alopecia areata who responded well to a combination therapy of 88% phenol and dexamethasone, with no recurrence observed during six months of follow-up.

This review discusses the potential role of systemic corticosteroids in the treatment of progressive vitiligo, but reports no new clinical results and suggests further research is needed.

This systematic review of pulse corticosteroid therapy for alopecia areata found relatively low complete response rates, but responders experienced low relapse rates, indicating potential benefits for patients with favorable prognostic factors.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

This study reviewed evidence suggesting that systemic corticosteroids, particularly in pulse regimens like dexamethasone and betamethasone oral mini-pulse, effectively slow vitiligo progression and support repigmentation, while offering a favorable safety profile compared to continuous therapy.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.

This study found that using methotrexate with corticosteroids may support hair regrowth in severe alopecia areata, but adverse effects and relapses were common, suggesting more controlled trials are needed.

Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.